These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 21885487

  • 41. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 42. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 43. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.
    Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG.
    Ann N Y Acad Sci; 2009 Sep; 1173():837-46. PubMed ID: 19758236
    [Abstract] [Full Text] [Related]

  • 44. The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study.
    Moen K, Kvalvik AG, Hellem S, Jonsson R, Brun JG.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Oct; 100(4):433-40. PubMed ID: 16182164
    [Abstract] [Full Text] [Related]

  • 45. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 46. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 47. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, Wendling D, le Noach J, Lohse A, Lecuyer E, Cri L.
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [Abstract] [Full Text] [Related]

  • 48. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 49. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.
    Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J.
    Ann Rheum Dis; 2014 Jun; 73(6):1138-43. PubMed ID: 23666932
    [Abstract] [Full Text] [Related]

  • 50. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.
    Arkema EV, Neovius M, Joelsson JK, Simard JF, van Vollenhoven RF.
    Ann Rheum Dis; 2012 Jul; 71(7):1203-6. PubMed ID: 22504565
    [Abstract] [Full Text] [Related]

  • 51. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 52. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y.
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract] [Full Text] [Related]

  • 53. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May 15; 57(4):679-85. PubMed ID: 17471545
    [Abstract] [Full Text] [Related]

  • 54. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
    Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.
    Arthritis Rheum; 2008 Mar 15; 58(3):667-77. PubMed ID: 18311816
    [Abstract] [Full Text] [Related]

  • 55. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study.
    Espiño-Lorenzo P, Manrique-Arija S, Ureña I, Jiménez-Núñez FG, López-Lasanta M, Romero-Barco CM, Belmonte-López MA, Irigoyen MV, Fernández-Nebro A.
    Reumatol Clin; 2013 Mar 15; 9(1):18-23. PubMed ID: 22938792
    [Abstract] [Full Text] [Related]

  • 56. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep 15; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 57. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May 15; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 58. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr 15; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 59. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B, Belch JJ, Pullar T, Ogston S, Khan F.
    J Rheumatol; 2010 Mar 15; 37(3):521-8. PubMed ID: 20080919
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.